GLP1R and Stroke: Meanwhile GLP-1 receptor agonists such as liraglutide (LEADER), semaglutide (SUSTAIN-6, PIONEER 6, SELECT), and dulaglutide (REWIND) demonstrated reduction in the risk of major adverse cardiovascular events (MACE) as well as stroke and cardiovascular risk.